Treatment, risk factors, and outcome of adults with relapsed AML after reduced intensity conditioning for allogeneic stem cell transplantation

Christoph Schmid, Myriam Labopin, Arnon Nagler, Dietger Niederwieser, Luca Castagna, Reza Tabrizi, Michael Stadler, Jürgen Kuball, Jan Cornelissen, Jiri Vorlicek, Gerard Socié, Michele Falda, Lars Vindeløv, Per Ljungman, Graham Jackson, Nicolaus Kröger, Andreas Rank, Emmanuelle Polge, Vanderson Rocha, Mohamad Mohty

Research output: Contribution to journalArticle

132 Citations (Scopus)

Abstract

Because information on management and outcome of AML relapse after allogeneic hematopoietic stem cell transplantation (HSCT) with reduced intensity conditioning (RIC) is scarce, a retrospective registry study was performed by the Acute LeukemiaWorking Party of EBMT. Among 2815 RIC transplants performed for AML in complete remission (CR) between 1999 and 2008, cumulative incidence of relapse was 32% ± 1%. Relapsed patients (263) were included into a detailed analysis of risk factors for overall survival (OS) and building of a prognostic score. CR was reinduced in 32%; remission duration after transplantation was the only prognostic factor for response (P = .003). Estimated 2-year OS from relapse was 14%, thereby resembling results of AML relapse after standard conditioning. Among variables available at the time of relapse, remission after HSCT>5 months (hazard ratio [HR] = 0.50, 95% confidence interval [CI], 0.37-0.67, P <.001), bone marrow blasts less than 27% (HR = 0.53, 95% CI, 0.40-0.72, P <.001), and absence of acute GVHD after HSCT (HR = 0.67, 95% CI, 0.49-0.93, P = .017) were associated with better OS. Based on these factors, 3 prognostic groups could be discriminated, showing OS of 32% ± 7%, 19% ± 4%, and 4% ± 2% at 2 years (P <.0001). Long-term survival was achieved almost exclusively after successful induction of CR by cytoreductive therapy, followed either by donor lymphocyte infusion or second HSCT for consolidation.

Original languageEnglish
Pages (from-to)1599-1606
Number of pages8
JournalBlood
Volume119
Issue number6
DOIs
Publication statusPublished - Feb 9 2012

Fingerprint

Stem Cell Transplantation
Stem cells
Hematopoietic Stem Cell Transplantation
Recurrence
Hazards
Survival
Confidence Intervals
Transplants
Lymphocytes
Therapeutics
Remission Induction
Information Management
Consolidation
Bone
Registries
Retrospective Studies
Transplantation
Bone Marrow
Tissue Donors
Incidence

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

Treatment, risk factors, and outcome of adults with relapsed AML after reduced intensity conditioning for allogeneic stem cell transplantation. / Schmid, Christoph; Labopin, Myriam; Nagler, Arnon; Niederwieser, Dietger; Castagna, Luca; Tabrizi, Reza; Stadler, Michael; Kuball, Jürgen; Cornelissen, Jan; Vorlicek, Jiri; Socié, Gerard; Falda, Michele; Vindeløv, Lars; Ljungman, Per; Jackson, Graham; Kröger, Nicolaus; Rank, Andreas; Polge, Emmanuelle; Rocha, Vanderson; Mohty, Mohamad.

In: Blood, Vol. 119, No. 6, 09.02.2012, p. 1599-1606.

Research output: Contribution to journalArticle

Schmid, C, Labopin, M, Nagler, A, Niederwieser, D, Castagna, L, Tabrizi, R, Stadler, M, Kuball, J, Cornelissen, J, Vorlicek, J, Socié, G, Falda, M, Vindeløv, L, Ljungman, P, Jackson, G, Kröger, N, Rank, A, Polge, E, Rocha, V & Mohty, M 2012, 'Treatment, risk factors, and outcome of adults with relapsed AML after reduced intensity conditioning for allogeneic stem cell transplantation', Blood, vol. 119, no. 6, pp. 1599-1606. https://doi.org/10.1182/blood-2011-08-375840
Schmid, Christoph ; Labopin, Myriam ; Nagler, Arnon ; Niederwieser, Dietger ; Castagna, Luca ; Tabrizi, Reza ; Stadler, Michael ; Kuball, Jürgen ; Cornelissen, Jan ; Vorlicek, Jiri ; Socié, Gerard ; Falda, Michele ; Vindeløv, Lars ; Ljungman, Per ; Jackson, Graham ; Kröger, Nicolaus ; Rank, Andreas ; Polge, Emmanuelle ; Rocha, Vanderson ; Mohty, Mohamad. / Treatment, risk factors, and outcome of adults with relapsed AML after reduced intensity conditioning for allogeneic stem cell transplantation. In: Blood. 2012 ; Vol. 119, No. 6. pp. 1599-1606.
@article{681cbe879ec24cac9a8132020972eec4,
title = "Treatment, risk factors, and outcome of adults with relapsed AML after reduced intensity conditioning for allogeneic stem cell transplantation",
abstract = "Because information on management and outcome of AML relapse after allogeneic hematopoietic stem cell transplantation (HSCT) with reduced intensity conditioning (RIC) is scarce, a retrospective registry study was performed by the Acute LeukemiaWorking Party of EBMT. Among 2815 RIC transplants performed for AML in complete remission (CR) between 1999 and 2008, cumulative incidence of relapse was 32{\%} ± 1{\%}. Relapsed patients (263) were included into a detailed analysis of risk factors for overall survival (OS) and building of a prognostic score. CR was reinduced in 32{\%}; remission duration after transplantation was the only prognostic factor for response (P = .003). Estimated 2-year OS from relapse was 14{\%}, thereby resembling results of AML relapse after standard conditioning. Among variables available at the time of relapse, remission after HSCT>5 months (hazard ratio [HR] = 0.50, 95{\%} confidence interval [CI], 0.37-0.67, P <.001), bone marrow blasts less than 27{\%} (HR = 0.53, 95{\%} CI, 0.40-0.72, P <.001), and absence of acute GVHD after HSCT (HR = 0.67, 95{\%} CI, 0.49-0.93, P = .017) were associated with better OS. Based on these factors, 3 prognostic groups could be discriminated, showing OS of 32{\%} ± 7{\%}, 19{\%} ± 4{\%}, and 4{\%} ± 2{\%} at 2 years (P <.0001). Long-term survival was achieved almost exclusively after successful induction of CR by cytoreductive therapy, followed either by donor lymphocyte infusion or second HSCT for consolidation.",
author = "Christoph Schmid and Myriam Labopin and Arnon Nagler and Dietger Niederwieser and Luca Castagna and Reza Tabrizi and Michael Stadler and J{\"u}rgen Kuball and Jan Cornelissen and Jiri Vorlicek and Gerard Soci{\'e} and Michele Falda and Lars Vindel{\o}v and Per Ljungman and Graham Jackson and Nicolaus Kr{\"o}ger and Andreas Rank and Emmanuelle Polge and Vanderson Rocha and Mohamad Mohty",
year = "2012",
month = "2",
day = "9",
doi = "10.1182/blood-2011-08-375840",
language = "English",
volume = "119",
pages = "1599--1606",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "6",

}

TY - JOUR

T1 - Treatment, risk factors, and outcome of adults with relapsed AML after reduced intensity conditioning for allogeneic stem cell transplantation

AU - Schmid, Christoph

AU - Labopin, Myriam

AU - Nagler, Arnon

AU - Niederwieser, Dietger

AU - Castagna, Luca

AU - Tabrizi, Reza

AU - Stadler, Michael

AU - Kuball, Jürgen

AU - Cornelissen, Jan

AU - Vorlicek, Jiri

AU - Socié, Gerard

AU - Falda, Michele

AU - Vindeløv, Lars

AU - Ljungman, Per

AU - Jackson, Graham

AU - Kröger, Nicolaus

AU - Rank, Andreas

AU - Polge, Emmanuelle

AU - Rocha, Vanderson

AU - Mohty, Mohamad

PY - 2012/2/9

Y1 - 2012/2/9

N2 - Because information on management and outcome of AML relapse after allogeneic hematopoietic stem cell transplantation (HSCT) with reduced intensity conditioning (RIC) is scarce, a retrospective registry study was performed by the Acute LeukemiaWorking Party of EBMT. Among 2815 RIC transplants performed for AML in complete remission (CR) between 1999 and 2008, cumulative incidence of relapse was 32% ± 1%. Relapsed patients (263) were included into a detailed analysis of risk factors for overall survival (OS) and building of a prognostic score. CR was reinduced in 32%; remission duration after transplantation was the only prognostic factor for response (P = .003). Estimated 2-year OS from relapse was 14%, thereby resembling results of AML relapse after standard conditioning. Among variables available at the time of relapse, remission after HSCT>5 months (hazard ratio [HR] = 0.50, 95% confidence interval [CI], 0.37-0.67, P <.001), bone marrow blasts less than 27% (HR = 0.53, 95% CI, 0.40-0.72, P <.001), and absence of acute GVHD after HSCT (HR = 0.67, 95% CI, 0.49-0.93, P = .017) were associated with better OS. Based on these factors, 3 prognostic groups could be discriminated, showing OS of 32% ± 7%, 19% ± 4%, and 4% ± 2% at 2 years (P <.0001). Long-term survival was achieved almost exclusively after successful induction of CR by cytoreductive therapy, followed either by donor lymphocyte infusion or second HSCT for consolidation.

AB - Because information on management and outcome of AML relapse after allogeneic hematopoietic stem cell transplantation (HSCT) with reduced intensity conditioning (RIC) is scarce, a retrospective registry study was performed by the Acute LeukemiaWorking Party of EBMT. Among 2815 RIC transplants performed for AML in complete remission (CR) between 1999 and 2008, cumulative incidence of relapse was 32% ± 1%. Relapsed patients (263) were included into a detailed analysis of risk factors for overall survival (OS) and building of a prognostic score. CR was reinduced in 32%; remission duration after transplantation was the only prognostic factor for response (P = .003). Estimated 2-year OS from relapse was 14%, thereby resembling results of AML relapse after standard conditioning. Among variables available at the time of relapse, remission after HSCT>5 months (hazard ratio [HR] = 0.50, 95% confidence interval [CI], 0.37-0.67, P <.001), bone marrow blasts less than 27% (HR = 0.53, 95% CI, 0.40-0.72, P <.001), and absence of acute GVHD after HSCT (HR = 0.67, 95% CI, 0.49-0.93, P = .017) were associated with better OS. Based on these factors, 3 prognostic groups could be discriminated, showing OS of 32% ± 7%, 19% ± 4%, and 4% ± 2% at 2 years (P <.0001). Long-term survival was achieved almost exclusively after successful induction of CR by cytoreductive therapy, followed either by donor lymphocyte infusion or second HSCT for consolidation.

UR - http://www.scopus.com/inward/record.url?scp=84856857935&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856857935&partnerID=8YFLogxK

U2 - 10.1182/blood-2011-08-375840

DO - 10.1182/blood-2011-08-375840

M3 - Article

VL - 119

SP - 1599

EP - 1606

JO - Blood

JF - Blood

SN - 0006-4971

IS - 6

ER -